Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.
In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelics Industry News Stories for the Week of April 19th – 25th, 2021.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view the full article.
A Bill to Decriminalize Psychedelic Substances in California is Quickly Moving up the Legislative Ladder
Introduced in February by Sen. Scott Wiener, SB 519 would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychoactive drugs including Psilocybin, psilocyn, DMT, Ibogaine, Mescaline, LSD, Ketamine and MDMA. The legislation would also expunge the criminal records of those charged with low-level Psychedelics convictions.
Lawmakers in the U.S. House of Representatives Have Introduced Three New Bills to Make State-Legal Marijuana Businesses Eligible for Federal Small Business Services, Including Loans, Disaster Relief and Grant Programs
The package of legislation is aimed at establishing parity for cannabis businesses, which are currently prohibited from receiving federal aid due to marijuana still being classified as a Schedule I controlled substance. The country’s legal cannabis industry nevertheless now supports nearly 320,000 full-time jobs in the U.S., according to industry estimates.
A Federal Health Agency Kicked Off a Speaker Series on Thursday That’s Dedicated to Recapping Science on the Therapeutic Potential of Psilocybin Mushrooms
And the experts who spoke at the first event said in response to Marijuana Moment’s questions that federal drug laws are out of step with voters and undermine the research objectives of the scientific community. The National Cancer Institute (NCI), under the National Institutes of Health (NIH), which is hosting the events, says that while federal law classifies the psychedelic as a Schedule I substance with no currently accepted medical value, …